Pierre BLANCHARD, MD, PhD - Clinical Trial Investigator | Syfrah

Trials Sponsors Conditions Drugs Pricing

Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(2)

MIXED(2)

ADT (Standard of Care)

Stereotactic Body RadioTherapy (SBRT)

4 unique interventions2 categories

Analytics

Trial Phases

Phase 31

Trial Status

Recruiting1

Role Distribution

Other Roles1

Activity Timeline

Clinical Trials (1)

NCT06625970Phase 3Recruiting

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

High Risk Prostate CarcinomaProstate Cancer

StudychairStart date: 2025-04-10

Research Network

Collaboration Network

4 collaborators·4 connections

Network Legend

KOL

Current Investigator

CO

High-influence Collaborator

CO

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

High Risk Prostate Carcinoma1 Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).1 Prostate Cancer1

Affiliations

Gustave Roussy, Cancer Campus, Grand Paris

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Karim Fizazi, MD, PhD

Gustave Roussy, Cancer Campus, Grand Paris

Moderately Similar

Shared therapeutic areas:

Prostate CancerHigh Risk Prostate CarcinomaPatients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

Worked with same sponsors:

Collaborated on 1 trial

Similarity Score34%

Gilles CREHANGE, MD, PhD

Institut Curie

Moderately Similar

Shared therapeutic areas:

High Risk Prostate CarcinomaPatients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).Prostate Cancer

Worked with same sponsors:

Collaborated on 1 trial

Similarity Score34%

Kevin Volpp, MD, PhD

University of Pennsylvania

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Neha sharma, PhD

Warwick Research Services

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Zhaohui Zhu, MD

Peking Union Medical College Hospital

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Barbara Murphy, MD

Vanderbilt-Ingram Cancer Center

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Charles L. Loprinzi, MD

Mayo Clinic

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Gregory Reid, MSc, MBA

MethylGene Inc.

Shared therapeutic areas:

Prostate Cancer

Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06625970Phase 3StudyChair

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

High Risk Prostate CarcinomaProstate Cancer

Recruiting

All 1 trials loaded